BIIB (Biogen Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BIIB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Michael Parini | Chief Legal Officer | A | — | — |
| 2026-08-05 | Lloyd Minor | Director | Sell | — | — |
| 2026-06-11 | Maria C Freire | Director | A | — | — |
| 2026-06-11 | Eric K Rowinsky | Director | A | — | — |
| 2026-06-11 | Lloyd Minor | Director | A | — | — |
| 2026-06-11 | Monish D Patolawala | Director | A | — | — |
| 2026-06-11 | Jesus B Mantas | Director | A | — | — |
| 2026-06-11 | WILLIAM A HAWKINS | Director | A | — | — |
| 2026-06-11 | STEPHEN A SHERWIN | Director | A | — | — |
| 2026-06-11 | SUSAN LANGER | Director | A | — | — |
| 2026-06-11 | Menelas N Pangalos | Director | MIXED | — | — |
| 2026-05-05 | Adam Keeney | Head of Corporate Development | MIXED | — | — |
| 2026-04-03 | Sean Godbout | Chief Accounting Officer | MIXED | — | — |
| 2026-02-17 | SUSAN H ALEXANDER | EVP Chief Legal Officer | A | — | — |
| 2026-02-17 | Sean Godbout | Chief Accounting Officer | A | — | — |
| 2026-02-17 | Ginger Gregory | EVP, Human Resources | A | — | — |
| 2026-02-17 | Jane Grogan | Head of Research | A | — | — |
| 2026-02-17 | Rachid Izzar | Head of Global Product Strat. | A | — | — |
| 2026-02-17 | Adam Keeney | Head of Corporate Development | A | — | — |
| 2026-02-17 | Robin Kramer | Chief Financial Officer | A | — | — |
| 2026-02-17 | Nicole Murphy | Head of Pharm Ops and Tech | Buy | — | — |
| 2026-02-17 | Priya Singhal | Head of Development | A | — | — |
| 2026-02-17 | Christopher Viehbacher | President and CEO | A | — | — |
| 2026-02-10 | SUSAN H ALEXANDER | EVP Chief Legal Officer | MIXED | — | — |
| 2026-02-10 | Sean Godbout | Chief Accounting Officer | MIXED | — | — |
| 2026-02-10 | Ginger Gregory | EVP, Human Resources | MIXED | — | — |
| 2026-02-10 | Jane Grogan | Head of Research | MIXED | — | — |
| 2026-02-10 | Rachid Izzar | Head of Global Product Strat. | MIXED | — | — |
| 2026-02-10 | Adam Keeney | Head of Corporate Development | MIXED | — | — |
| 2026-02-10 | Robin Kramer | Chief Financial Officer | MIXED | — | — |
| 2026-02-10 | Nicole Murphy | Head of Pharm Ops and Tech | MIXED | — | — |
| 2026-02-10 | Priya Singhal | Head of Development | MIXED | — | — |
| 2026-02-10 | Christopher Viehbacher | President and CEO | MIXED | — | — |
| 2026-02-03 | Priya Singhal | Head of Development | MIXED | — | — |
| 2025-12-03 | Christopher Viehbacher | President and CEO | MIXED | — | — |
| 2025-11-04 | Jane Grogan | Head of Research | MIXED | — | — |
| 2025-10-06 | Sean Godbout | Chief Accounting Officer | MIXED | — | — |
| 2025-09-02 | Priya Singhal | Head of Development | MIXED | — | — |
| 2025-07-16 | Rachid Izzar | Head of Global Product Strat. | Sell | — | — |
| 2025-06-18 | CAROLINE DORSA | Director | A | — | — |
| 2025-06-18 | SUSAN LANGER | Director | A | — | — |
| 2025-06-18 | STEPHEN A SHERWIN | Director | A | — | — |
| 2025-06-18 | Eric K Rowinsky | Director | A | — | — |
| 2025-06-18 | Maria C Freire | Director | A | — | — |
| 2025-06-18 | WILLIAM A HAWKINS | Director | A | — | — |
| 2025-06-18 | Jesus B Mantas | Director | A | — | — |
| 2025-06-18 | Monish D Patolawala | Director | A | — | — |
| 2025-06-18 | Lloyd Minor | Director | A | — | — |
| 2025-06-18 | Menelas N Pangalos | Director | A | — | — |
| 2025-05-20 | Priya Singhal | Head of Development | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 658,099 | — |
| — | Director | 470,278 | — |
| — | CEO & President | 197,896 | — |
| — | President, R & D | 88,732 | — |
| — | Chief Executive Officer | 70,007 | — |
| — | EVP, Corp. Strategy and Comm. | 63,603 | — |
| — | EVP Chief Legal Officer | 63,403 | — |
| — | Chief Executive Officer | 60,157 | — |
| — | Chief Operating Officer | 53,261 | — |
| — | Director | 47,250 | — |
| — | EVP, Portfolio Strategy | 43,778 | — |
| — | EVP Pharmaceutical Oper & Tech | 39,045 | — |
| — | Director | 31,002 | — |
| — | Chief Operating Officer | 28,625 | — |
| — | Director | 27,470 | — |
| — | Director | 25,844 | — |
| — | EVP, Chief Financial Officer | 25,712 | — |
| — | EVP, Oncology/Rheumatology SBU | 25,454 | — |
| — | President and CEO | 25,451 | — |
| — | EVP, New Ventures | 24,752 | — |
| — | EVP Corp. and Bus. Dev. | 23,457 | — |
| — | EVP, Human Resources | 22,358 | — |
| — | EVP Corporate & Business Devel | 21,104 | — |
| — | Director | 20,632 | — |
| — | Head of Pharm Ops and Tech | 19,611 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BIIB quote page; the site-wide leaderboard is on the insider transactions hub.